Abstract |
High-dose chemotherapy and autologous stem cell transplant (ASCT) remains a cornerstone of treatment in relapsed/refractory (R/R) aggressive-histology lymphomas. This retrospective study examined efficacy and safety of peripheral blood stem cell (PBSC) mobilization using cyclophosphamide/ etoposide and GCSF (CE + GCSF, n = 129) versus gemcitabine, dexamethasone and cisplatin and GCSF (GDP + GCSF, n = 210). All patients received first salvage with GDP. Patients mobilized with CE + GCSF required fewer days of leukapheresis (median 1 vs 2 day; p = .001) and achieved higher total CD34+ yield than GDP + GCSF patients (8.5 vs 7.1 × 106 CD34+ cells/kg, p = .001). Rates of febrile neutropenia and CD34+ collection ≥5 × 106 CD34+ cells/kg were similar (OR 1.19, 95% CI: 0.54-2.6, p = .66). In multivariable analysis, days to engraftment and admission duration were not statistically different between the two mobilization strategies. While CE + GCSF appeared more efficacious for mobilization after GDP salvage, this did not translate to significant differences in clinical outcomes.
|
Authors | Catherine Tang, Osvaldo Espin-Garcia, Anca Prica, Vishal Kurkreti, Robert Kridel, Armand Keating, Christopher J Patriquin, John Kuruvilla, Michael Crump |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 61
Issue 9
Pg. 2153-2160
(09 2020)
ISSN: 1029-2403 [Electronic] United States |
PMID | 32482114
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Deoxycytidine
- Etoposide
- Dexamethasone
- Cisplatin
- Gemcitabine
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Cisplatin
(therapeutic use)
- Deoxycytidine
(analogs & derivatives)
- Dexamethasone
(therapeutic use)
- Etoposide
(therapeutic use)
- Hematopoietic Stem Cell Mobilization
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma
(drug therapy)
- Retrospective Studies
- Salvage Therapy
- Gemcitabine
|